

Research Note:

Vitamin D in Cats with Liver Disease

Humans with chronic cholestatic liver disease (CLD) have deficiencies in vitamin D. Cats with inflammatory bowel disease, intestinal small cell lymphoma, and some infections have also been shown to be deficient in vitamin D. This prospective study compared vitamin D levels in cats with CLD with vitamin D levels in cats with nonhepatobiliary illness. Median serum vitamin D levels were similar between the groups, although low vitamin D occurred in a greater percentage of cats with CLD. Lower vitamin D was moderately correlated with higher WBC counts. Further study into the cause and clinical significance of these findings is warranted.

Source

Kibler L, Heinze CR, Webster CRL. Serum vitamin D status in sick cats with and without cholestatic liver disease. *J Feline Med Surg*. 2020;22(10):944-952.

LOOK FOR THESE ARTICLES IN FUTURE ISSUES

- ▶ Top 5 Fine-Needle Biopsy Sample Collection & Handling Errors
- ▶ Tracheal Collapse
- ▶ Toxicology Cases
- ▶ Hindlimb Amputation
- ▶ Electrocuting Emergency in a Puppy

Osurnia[®]

(florfenicol-terbinafine-betamethasone acetate)

Otic gel

For Otic Use in Dogs Only

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

BRIEF SUMMARY (for full prescribing information, see package insert)

DESCRIPTION: OSURNIA contains 10 mg florfenicol, 10 mg terbinafine and 1 mg betamethasone acetate per mL and the inactive ingredients propylene carbonate, glycerol formal, hypromellose, phospholipid, oleic acid and BHT in an off-white to slightly yellow translucent gel.

INDICATION: OSURNIA is indicated for the treatment of otitis externa in dogs associated with susceptible strains of bacteria (*Staphylococcus pseudintermedius*) and yeast (*Malassezia pachydermatis*).

DOSAGE AND ADMINISTRATION: OSURNIA should be administered in the clinic. Clean and dry the external ear canal before administering the initial dose of the product. Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days. Do not clean the ear canal for 45 days after the initial administration to allow contact of the gel with the ear canal. Cleaning the ear may affect product effectiveness (see **Effectiveness** in the product insert). If alternative otic therapies are required it is recommended to clean the ear(s) before application. Open tube by twisting the soft tip. Insert the flexible tip into the affected external ear canal(s) and squeeze entire tube contents into the external ear canal(s). After application, gently massage the base of the ear to allow the gel to penetrate to the lower part of the ear canal.

CONTRAINDICATIONS: Do not use in dogs with known tympanic perforation (see **Precautions** in the product insert). Do not use in dogs with a hypersensitivity to florfenicol, terbinafine, or corticosteroids.

WARNINGS: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. In case of accidental skin contact, wash area thoroughly with water. Avoid contact to the eyes.

PRECAUTIONS: Do not administer orally. The use of OSURNIA in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering this product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see **Animal Safety** in the product insert). Use with caution in dogs with impaired hepatic function (see **Animal Safety and Adverse Reactions** in the product insert). The safe use of OSURNIA in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

ADVERSE REACTIONS: The following adverse reactions were reported during the course of a US field study for treatment of otitis externa in dogs treated with OSURNIA with 1 tube per affected ear(s) and repeated after 7 days. The following adverse events are listed in decreasing order: elevated alkaline phosphatase, vomiting, elevated AST, ALT, ALP, weight loss (>10% body weight), and hearing decrease/loss. To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Dechra Veterinary Products at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

EFFECTIVENESS: Effectiveness was evaluated in 235 dogs with otitis externa. The study was a double-masked field study with a placebo control (vehicle without the active ingredients). One hundred and fifty-nine dogs were treated with OSURNIA and seventy-six dogs were treated with the placebo control. All dogs were evaluated for safety. Treatment (1 mL) was administered to the affected ear(s) and repeated 7 days later. Prior to the first administration, the ear(s) were cleaned with saline but not prior to the Day 7 administration. Six clinical signs associated with otitis externa were evaluated: pain, erythema, exudate, swelling, odor and ulceration. Total clinical scores were assigned for a dog based on the severity of each clinical sign on Days 0, 7, 14, 30 and 45. Success was determined by clinical improvement at Day 45. The success rates of the two groups were significantly different ($p=0.0094$); 64.78% of dogs administered OSURNIA were successfully treated, compared to 43.42% of the dogs in the placebo control group.

STORAGE: OSURNIA should be stored under refrigerated conditions between 36° - 46° F (2° - 8° C). To facilitate comfort during administration, OSURNIA may be brought to room temperature and stored for up to three months.

MANUFACTURED FOR:
Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211 USA

Product of Great Britain

NADA # 141-437, Approved by FDA

OSURNIA is a registered trademark of Dechra Limited. All rights reserved.

